Soleno治疗技术公司获得200万美元资金,用于推进Prader-Willi综合症的治疗。 Soleno Therapeutics secures $200M financing to advance Prader-Willi syndrome treatment.

Soleno治疗技术公司与牛津金融有限公司达成了一项2亿美元的债务融资协议,以支持其治疗Prader-Willi综合症的商业启动计划。 Soleno Therapeutics has secured a $200 million debt financing deal with Oxford Finance LLC to support its commercial launch plans for treating Prader-Willi syndrome. 该交易包括最初的 5000 万美元提款，额外资金取决于 FDA 的批准和商业里程碑。 The deal includes an initial $50 million draw, with additional funds contingent on FDA approval and commercial milestones. 这笔资金将索莱诺的现金储备提高到3.347亿美元,增强了其开发其主要候选人DCCR并将其商业化的能力。 This financing boosts Soleno’s cash reserves to $334.7 million, enhancing its ability to develop and commercialize its lead candidate, DCCR.